

SHIVAPUTRA A. PATIL *Ph.D.*

Assistant Professor, Research, (O): HSB, Room 2.627
Pharmaceutical Sciences Department, College of Pharmacy
Rosalind Franklin University of Medicine and Science
3333 Green Bay Road, North Chicago, IL 60064
Phone: 847-578-8383; Cell: 901 246 4515
E-mail: shivaputra.patil@rosalindfranklin.edu
shivaputrap@yahoo.com

PERSONAL: Citizenship: USA (*By Naturalization*).

EDUCATION:

Ph.D. (1998): Ph.D. Thesis topic: “**Synthetic Studies on Nitrogen Heterocycles**”.
Karnatak University, Dharwad, India.

M. Sc. (1993): *Organic Chemistry:* Karnatak University, Dharwad, India.

B. Sc. (1991): *Chemistry:* Karnatak University, Dharwad, India.

EMPLOYMENT:

2015-Present: Assistant Professor, Research, Rosalind Franklin University, North Chicago, USA

2014-2015: Assistant Professor, Adjunct, Rosalind Franklin University, North Chicago, USA

2010- 2014: Assistant Professor, Research, University of Tennessee Health Science Center
Memphis, TN, USA.

2005-2010: Staff Research Associate, University of Tennessee Health Science Center,
Memphis, TN, USA.

2003- 2005: Postdoctoral Fellow, University of Tennessee Health Science Center,
Memphis, TN, USA.

2002-2003: Postdoctoral Fellow, City College of CUNY, New York, USA.

2001- 2002: Postdoctoral Fellow, University of WITS, Johannesburg, South Africa.

1999- 2000: Technical Officer, ICI India Ltd., Mumbai, India.

1998- 1999: Research Associate, ICI India Ltd., Mumbai, India.

PROFESSIONAL SOCIETY MEMBERSHIP:

2002 – Present: Member of American Chemical Society (ACS) including local ACS.

HONORS:

2015: Research and Scholarship report (2014-15), College of Pharmacy, RFUMS;
Appeared on cover page photo for publishing highest articles.

2015: Research article highlights- Future Medicinal Chemistry (Future Science Group)-
Patil et al, 2012, 'Indole molecules as inhibitors of tubulin polymerization:
Potential new anticancer agents', is within the top 20 most cited articles published
between 2012 and 2014.

- 2015:** Research article highlights –Medicinal Chemistry (Bentham Science) journal selected our research article for the cover page.
- 2015:** Featured Research article: Appeared in *ScienceDaily*, January 22nd; Promising drug candidate protects against radiation exposure from nuclear fallout and also appeared in *NewScientist Magazine* (London), January 22nd; Anti-radiation drug could work days after exposure.
Original article: Patil et al., *Chemistry & Biology- 2015*; "Combined Mitigation of the Gastrointestinal and Hematopoietic Acute Radiation Syndromes by a Novel LPA2 Receptor-specific Non-lipid Agonist"
- 2014:** Research news highlights - UT College of Pharmacy Newsletter (February); The Research Note Book, A publication of the Office of Research (January)
- 2013:** University of Tennessee Research Foundation (UTRF) Innovation Award.
- 2010:** Strathmore's Who's Who Worldwide.
- 2009:** Marquis Who's Who in America.
- 2001-2002:** Recipient of National Research Foundation Fellowship: Witwatersrand University, Johannesburg, South Africa.
- 1996- 1998:** Recipient of Senior Research Fellowship: CSIR New Delhi.
- 1991:** Received First Prize in B.Sc. part-III.
- 1990:** Received First Prize in B.Sc. part-II.
- 1986:** Received first prize in High School.

EDITORIAL BOARD MEMBER:

Organic Chemistry: Current Research Journal (OMICS Publishing Group)

International Journal of Bioorganic Chemistry & Molecular Biology (IJBCMB) (SCIDOC Publishers)

REVIEWER:

Journal of Medicinal Chemistry (American Chemical Society)

Bioorganic and Medicinal Chemistry (Elsevier)

Bioorganic and Medicinal Chemistry Letters (Elsevier)

ChemBioChem (Wiley)

Letters in Drug Design & Discovery (Bentham Science)

Current Organic Synthesis (Bentham Science)

Anti-Cancer Agents in Medicinal Chemistry (Bentham Science)

Current Green Chemistry (Bentham Science)

Future Medicinal Chemistry (Future Science Group)

Molecules (Open Access Organic Chemistry Journal)

Organic Chemistry: Current Research Journal (OMICS Publishing Group)

Chemotherapy: Open Access (OMICS Publishing Group)

Arabian Journal of Chemistry (Elsevier)

Organic & Biomolecular Chemistry (Royal Society of Chemistry)

OTHER PROFESSIONAL SERVICE ACTIVITIES:

2013: Graduate Research Day: Judge; Graduate Poster Presentations.
2011: Conducted Journal Club for graduate students.
2010-2014: Manager of Discover LabMate Microwave instrument, taught graduate students and postdocs about this instrument and its utilization.
1990-1991: Secretary (Sport): SSMS College, Karnatak University, India.
1990-1991: National Service Scheme (NSS) volunteered in B.Sc.

TEACHING:

2010-2014: Taught portion of PHSC 112, Medicinal Chemistry I course to PharmD first year students (topics: steroids and cholinergics).

2012: Taught portion of MEDC 812, Advanced Medicinal Chemistry course to graduate students.

2009-2010: Taught organic chemistry for the MCAT/PCAT/DAT students as Chemistry Faculty at Tennessee Institutes for the Pre-Professionals (TIP), Summer Science Institute (SSI), University of Tennessee Health Science Center, Memphis, TN.

2006- 2007: Taught organic chemistry courses **CHEM 3311** and **CHEM 3312** at University of Memphis as adjunct faculty.

RESEARCH:

The major emphasis of my research is to design and develop novel chemotherapeutic agents for cancer which is one of the leading causes of deaths. New chemotherapeutic agents are needed for the improved treatment of cancer. Drug design efforts are focused on the initial hits developed either by initial screening processes or developed by medicinal chemistry efforts. Design, synthesis and detailed biological evaluation of new drug candidates are main objectives. My research topics are at the interface of chemistry and biology and wishes to collaborate with computational and biological research groups.

GRANTS:

Ongoing Research Support

1. RFUMS-DePaul University Pilot Grant **Patil;Waris;Grice (MPI)** 12/1/2015- 11/30/2017

“Novel Metal-Based Drugs as Anti-Cancer and Anti-Viral Therapies”

The main goal of this proposal is to develop novel chemotherapies for Cancer and chronic liver diseases associated with viral Hep C.

Role: Principle Investigator

Completed Research Support

1. Seed Research Grant (College of Pharmacy, UTHSC) **Patil S. (PI)** 9/01/2013-08/31/2014
“Discovery of novel chemotherapeutic agents to treat brain cancer”.

Main goal of this research is to discover novel chromene based antiglioma agents to treat brain cancer.

Role: Principal Investigator

2. Pilot data program research fund (UT Research Office) **Patil S. (PI)** 04/17/2013-4/16/2014
“Discovery of novel chemotherapeutic agents to treat brain cancer”.

This is multiple investigator effort with Dr. Duane D. Miller and the main goal is to discover the novel chromene based antiglioma agents to treat brain cancer.

Role: Principal Investigator

3. CEM Corporation, Matthews, NC. **Patil S. (PI)** 11/18/2013-12/31/2014
“Microwave-Enhanced Chemistry Grant”

The main goal of this instrument grant is to fully explore the microwave technology in medicinal chemistry synthesis to advance drug discovery research.

Role: Principal Investigator

4. Instrument grant (College of Pharmacy, UTHSC) **Jaggi M. (PI)** 9/01/2013-8/31/2014
“BD Accuri™ C6 Flow Cytometer”

Main goal of the project is high throughput screening of anti-cancer drugs for various identifying the anti-cancer efficacies of drugs through cellular studies.

Role: Co-Investigator

5. GTx, Inc., Memphis, TN **Miller D (PI)** 01/01/2013-10/31/2013
Selective androgen receptor modulators (SARMs) for anabolic therapy

The main purpose of this funding is to discover non-steroidal selective androgen receptor modulators (SARMs) for anabolic therapies that improve muscle and bone strength.

Role: Co-Investigator

6. GTx, Inc. Memphis **Miller D (PI)** 01/01/2012-12/31/2012
Selective androgen receptor modulators (SARMs) for anabolic therapy.

The main purpose of this funding is to discover non-steroidal selective androgen receptor modulators (SARMs) for anabolic therapies such as muscle and bone strength.

Role: Co-Investigator

NIH (NCI) SCORED BUT NOT FUNDED GRANTS:

1R15CA179449-01A1 (NCI) **Patil S (PI)** 08/01/2014-07/31/2017
Received the **impact score 49.**

“Identifying tumor permeable lead drug candidate for glioma”

The focus of this grant is to find new dual acting antiglioma agents with tumor permeable property along with antiglioma activity.

Role: Principal investigator

1R21CA175192-01A1 (NCI) **Patil S; Miller D. (MPI)** 10/01/2014- 09/01/2016

Received the **impact score 39** and **percentile 36**.

“Discovery of novel chemotherapeutic agents to treat brain cancer”

The focus of this grant is to find new chemotherapeutic agents based on our initial lead drug candidate (SP-6-27) for treating brain cancer. (**first submission received impact score: 39 and percentile: 36**)

Role: Principal investigator

MENTORING:

I mentored several graduate, PharmD, and summer students for design and synthesis of new small molecule drugs.

YEAR	STUDENT NAME
2013	Ahmed, A.
2013	Like, L.
2013	Weaver, W.
2010	Harrish, S.
2006	Nguyen, J.
2005	Kimberley, K.
2004	Marian, O.

PATENTS AND PATENT APPLICATIONS:

1. Inventors: Duane D. Miller, **Shivaputra A. Patil**, Renukadevi Patil, Terreia Jones, Amira Ahmed, Likeselam Asres, Charles Ryan Yates, Eldon Geisert. Compounds with increased specificity for the treatment of glioma. **2015**, Patent number: US 9187449.
2. Inventors: John K. Buolamwini, **Shivaputra A. Patil**, Horick Sharma, James K. Addo. 1-Aryl- or 1-heteroaryl-pyrido[*b*]indoles and uses thereof in treating cancers. **2012**, Patent number: US 8,329,723.
3. Inventors: Charles R. Yates, Duane D Miller, Frank Park, Jordan J. Toutouchian, Vanessa M. Morales-Tirado, **Shivaputra Patil**. Pagadala Jayaprakash, Bilal Abou Aleiwi. Inhibitors of paxillin function and related compositions and methods. **2015**, Publication number: WO 2015120059 A1 20150813.
4. Inventors: Duane D. Miller, **Shivaputra A. Patil**, Renukadevi Patil, Terreia Jones, Amira Ahmed, Likeselam Asres, Charles Ryan Yates, Eldon Geisert. Compounds for the treatment of glioma. **2014**, Publication number: WO 2014/160723 A1
5. Inventors: Duane D. Miller, **Shivaputra A. Patil**, Renukadevi Patil, Terreia Jones, Amira Ahmed, Likeselam Asres, Charles Ryan Yates, Eldon Geisert.

Compounds with increased specificity for the treatment of glioma. **2014**, Publication number: US20140296286 A1.

6. Inventors: Renukadevi Patil, **Shivaputra A. Patil**, Duane D. Miller, Charles R. Yates, Eldon L. Geisert.
1,2,3,4-Tetrahydroisoquinoline derivatives effective as antiglioma agents, methods of making, and their use. **2012**, Publication number: US20120059032 A1.
7. Inventors: John K. Buolamwini, **Shivaputra Patil**, James K. Addo, Parker D. Suttle, Ruiwen Zhang, Zhengxiang Zhu, Horrik Sharma.
1-Aryl-or 1-heteroaryl-pyrido[b]indoles and uses thereof. **2010**, Publication number: US20100317667 A1.

PROVISIONAL PATENT APPLICATIONS and PATENT DISCLOSURES:

8. Inventors: Charles R. Yates, Duane D Miller, Frank Park, Jordan J Toutounchian, **Shivaputra A. Patil**. Inhibitors of paxillin function and related compositions and methods. **2014**, Provisional application number: 61/935,616.
9. Inventors: James. T. Dalton, Duane D. Miller, Amanda Jones, **Shivaputra A. Patil**. Cyclohexanol based androgen receptor antagonists and methods of use thereof' **2012**, Provisional application number: 61/667,741.
10. Inventors: James. T. Dalton, Duane D. Miller, Amanda Jones, **Shivaputra A. Patil**. Cyclohexanol based androgen receptor modulators and methods of use thereof **2012**, Provisional application number: 61/667,730.
11. Inventors: John K. Buolamwini, **Shivaputra Patil** and Horrick Sharma.
Novel Chalcone derivative as HIV integrase inhibitors. **2010**, Patent disclosure number: 09083.
12. Inventors: Duane Miller, **Shivaputra Patil**, Wei Li, Anna N. Bukiya, and Alejandro M. Dopico.
Design and synthesis of hydroxyl-alkynoic acids and their methyl esters as novel activators of BK channels. **2008**, Patent disclosure number: 078855.
13. John K. Buolamwini and **Shivaputra Patil**
Novel Phenanthrene/Anthracene and Derivative Aryl Diketoacid HIV integrase Inhibitors for AIDS Therapy. **2007**, Patent disclosure number: 013801.

PUBLICATIONS (* indicates corresponding authorship):

1. **Patil SA***, Patil SA, Patil R, Hashizume R.
Imidazoquinolines: Recent developments in anticancer activity.
Mini-Reviews in Medicinal Chemistry, **2016**, 16(4), 309-22.
2. Banerjee S, Wang J, Pfeffer S, Ma D, Pfeffer LM, **Patil SA**, Li W, Miller DD.
Design, Synthesis, and Biological Evaluation of Novel 5H- Chromenopyridines as Potential

Anti-Cancer Agents.

Molecules, **2015**, 20, 17152.

3. Patil SA, **Patil SA**, Patil R, Keri RS, Budagumpi S, Balakrishna GR, Tacke M. N-heterocyclic carbene metal complexes as bioorganometallic antimicrobial and anticancer drugs. *Future Med. Chem.* **2015**, 7(10), 1305.
4. **Patil SA***, Patil SA, Patil R. Microwave-assisted synthesis of chromenes: Biological and chemical importance. *Future Med. Chem.* **2015**, 7(7), 893.
5. **Patil SA***, Pfeffer SR, Seibel WL, Pfeffer LM, Miller DD. Identification of potent imidazoquinoline derivatives as antiglioma agents from screening. *Medicinal Chemistry (Bentham Science)*, **2015**, 11(4), 400.
6. Nag S, Qin JJ, Voruganti S, Wang MH, Sharma H, **Patil S**, Buolamwini JK, Wang W, Zhang R. Development and validation of a rapid HPLC method for quantitation of SP-141, a novel pyrido[b]indole anticancer agent, and an initial pharmacokinetic study in mice. *Biomed. Chromatogr.*, **2015**, 29, 654.
7. Patil R, Szabó E, Fells JI, Balogh A, Lim KG, Fujiwara Y, Norman DD, Lee SC, Balazs L, Thomas F, **Patil S**, Emmons-Thompson K, Boler A, Strobos J, McCool SW, Yates CR, Stabenow J, Byrne GI, Miller DD, Tigyi GJ. Combined Mitigation of the Gastrointestinal and Hematopoietic Acute Radiation Syndromes by an LPA2 Receptor-Specific Nonlipid Agonist. *Chem Biol.* **2015**, 22, 206.
8. Wang W, Qin J-J, Voruganti S, Srivenugopal KS, Nag S, **Patil S**, Sharma H, Buolamwini JK, Zhang R. A novel pyrido[b]indole MDM2 inhibitor, SP-141, exerts potent therapeutic effects in breast cancer models. *Nature Communications*, **2014**, 5, 5086.
9. McMillan JE, Bukiya AN, **Patil SA**, Miller DD, Dopico AM, Parrill AL. Multi-generational pharmacophore modeling for ligands to the cholane steroid-recognition site in the β 1 modulatory subunit of the BKCa channel *Journal of Molecular Graphics and Modeling* **2014**, 54, 174.
10. Wang W, Qin J-J, Voruganti S, Wang M-H, Sharma H, **Patil S**, Zhou J, Wang H, Mukhopadhyay D, Buolamwini JK, Zhang R. Identification of a new class of MDM2 inhibitor that inhibits growth of orthotopic pancreatic tumors in mice. *Gastroenterology* **2014**, 147(4), 893.
11. Patil R, Fells JI, Szabó E, Lim KG, Norman DB, Balogh A, **Patil SA**, Strobos J, Miller DD, Tigyi GJ. Design and synthesis of sulfamoyl benzoic acid analogs with subnanomolar agonist activity specific to the LPA2 receptor. *Journal of Medicinal Chemistry* **2014**, 57(16), 7136.
12. Patil R, Hosni-Ahmed A, Jones TS, **Patil SA**, Asres LB, Wang X, Yates RC, Geisert EE, Miller DD. Synthesis and *in vitro* evaluation of novel 1,2,3,4-tetrahydroisoquinoline derivatives as potent antiglioma agents. *Anti-Cancer Agents in Medicinal Chemistry* **2014**, 14, 473.

13. Nag S, Qin JJ, **Patil S**, Deokar H, Buolamwini JK, Wang W, Zhang R.
A quantitative LC-MS/MS method for determination of SP-141, a novel pyrido[b]indole anticancer agent, and its application to a mouse PK study.
J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. **2014**, 969C, 235.
14. Ahmed AH, Sims M, Jones TS, Patil R, **Patil S**, Abdelsamed H, Yates CR, Miller DD, Pfeffer LM.
EDL-360: A potential novel anti-glioma agent.
J. Cancer Sci. Ther. **2014**, 6, 370.
15. **Patil SA***, Miller DD. (Editorial).
Current trends in medicinal chemistry.
Organic Chem. Curr. Res. **2013**, 2, e124.
16. **Patil SA***, Patil R, Pfeffer LM, Miller DD.
Chromenes: Potential new chemotherapeutic agents for cancer.
Future Med. Chem. **2013**, 5(14):1647.
17. **Patil SA***, Hosni-Ahmed A, Jones TS, Patil R, Pfeffer LM, Miller DD.
Novel approaches to glioma drug design and drug screening.
Expert Opin. Drug Discov. **2013**, 8(9), 1135.
18. **Patil SA***, Patil R, Miller DD.
Large conductance, calcium activated potassium (BK) channels as new therapeutic target for glioma.
International Journal of Bioorganic Chemistry & Molecular Biology **2013**, 1, 101.
19. Bukiya A, McMillan J, Fedinec A, **Patil S**, Miller D, Leffler C, Parrill A, Dopico A.
Cerebrovascular dilation via selective targeting of the cholane steroid-recognition site in the BK channel $\beta 1$ subunit by a novel nonsteroidal agent.
Mol. Pharmacol. **2013**, 83(5), 1030.
20. Bukiya AN, **Patil SA**, Li W, Miller DD, Dopico AM.
Structural requirements in the steroid lateral chain for the activation of $\beta 1$ subunit-containing BK channels by 5β -cholanic acid- 3α -Ol analogues.
Biophysical Journal **2013**, 104(2), 472a.
21. **Patil SA***, Patil R, Miller DD.
Indoles as tubulin polymerization inhibitors.
Future Medicinal Chemistry **2012**, 4(16), 2085.
22. **Patil SA*** (Editorial)
Role of medicinal chemist in the modern drug discovery and development.
Organic Chem. Curr. Res. **2012**, 1, e110.
23. Mohler M, Cross C, Duke C, **Patil S**, Miller D, Dalton J. Androgen receptor antagonists: A patent review (2008-2011).
Expert Opinion on Therapeutic Patents **2012**, 22 (5), 541.
24. Wang XD, Freeman NE, Patil R, **Patil S**, Mitra S, Orr WE, Abner CW, Yates CR, Miller DD Geisert EE.
EDL-291, a novel isoquinoline presents anti-glioblastoma effects *in vitro* and *in vivo*.
Anti-Cancer Drugs **2012**, 23(5), 494.
25. **Patil SA***, Wang J, Li XS, Chen J, Jones TS, Hosni- Ahmed A, Patil R, Seibel WL, Li W, Miller DD.
New substituted 4*H*-chromenes as anti-cancer agents.
Bioorg. Med. Chem. Lett. **2012**, 22(13), 4458.

26. **Patil SA***, Patil R, Miller DD.
Microwave-assisted synthesis of medicinally relevant indoles.
Current Medicinal Chemistry **2011**, 18, 615.
27. Sharma H, **Patil S**, Neamati N, Schinazi RF, Buolamwini JK.
Synthesis, biological evaluation and 3D-QSAR studies of 3-keto salicylic acid chalcones and related amides as novel HIV-1 integrase inhibitors.
Journal of Bio-Organic and Medicinal Chemistry **2011**, 19, 2030.
28. Patil R, **Patil S**, Wang X, Ma F, Orr WE, Li W, Yates CR, Geisert EE, Miller DD.
Synthesis and evaluation of new 1,2,3,4-tetrahydroisoquinoline analogs as antiglioma agents.
Medicinal Chemistry Research **2011**, 20(1), 131.
29. **Patil SA***, Patil R, Miller DD.
Solid phase synthesis of biologically important indoles.
Current Medicinal Chemistry **2009**, 16, 2531.
30. Luo W, Liu J, Li J, Zhang D, Liu M, Addo JA, **Patil S**, Zhang L, Yu J, Buolamwini JK, Chen J, Huang C.
Anti-cancer effects of JKA97 are associated with its induction of cell apoptosis via a Bax-dependent, and p53-independent pathway.
Journal of Biological Chemistry **2008**, 283(13), 8624.
31. **Patil SA***, Patil R, Miller DD.
Synthetic applications of the Nenitzescu reaction to biologically active 5-hydroxy indoles.
Current Organic Chemistry **2008**, 12, 691.
32. **Patil S**, Bukiya AN, Li W, Dopico AM, Miller D.
Design and synthesis of hydroxy-alkynoic acids and their methyl esters as novel activators of BK channels.
Bioorganic Medicinal Chemistry Letters **2008**, 18, 3427.
33. **Patil SA***, Patil R.
Synthesis and functionalization of indoles through rhodium-catalyzed reactions.
Current Organic Synthesis **2007**, 4, 201.
34. **Patil S**, Kamat S, Sanchez T, Neamati N, Schinazi RF, Buolamwini JK.
Synthesis and biological evaluation of novel 5(*H*)phenanthridin-6-ones, 5(*H*)phenanthridin-6-one diketoacid and polycyclic aromatic diketoacid analogs as new HIV-1 integrase inhibitors.
Bio-Organic and Medicinal Chemistry **2007**, 15, 1212.
35. **Patil S**, Buolamwini JK.
Recent uses of palladium catalyst in indole synthesis.
Current Organic Synthesis **2006**, 3, 477.
36. Buolamwini JK, Addo J, Kamath S, **Patil S**, Mason D, Marian Ores.
Small molecule antagonists of the MDM2 oncoprotein as anticancer agents.
Current Cancer Drug Targets **2005**, 5(1), 57.
37. Dinsmore A, Billing DG, Mandy K, Michael JP, Mogano D, **Patil S**.
Magnesiation employing Grignard reagents and catalytic amine. Application to the functionalization of *N*-phenylsulfonylpyrrole.
Organic Letters **2004**, 6(2), 293.
38. Gadaginamath GS, **Patil SA**, Donawade DS.
Synthesis and antimicrobial activity of 6-bromo-1-butyl-3-ethoxycarbonyl-2-(*N*-methyl-*N*-phenylamino) methyl-5-(1,2,3,4-tetrazol-5-yl) methoxyindole.
Indian J. Heterocyclic Chemistry **2004**, 14(2), 93.

39. Gadaginamath GS, **Patil SA**.
Synthesis and antimicrobial activity of 6-bromo-1-butyl-3-ethoxycarbonyl-2-(*n*-methyl-*N*-phenylamino) methyl-5(1,2,3,4-tetrazol-5-yl)methoxyindole.
Revue Roumaine de Chimie **2001**, 46(2), 99.
40. Gadaginamath GS, Kavali RR, **Patil SA**, Shyadligeri AS.
One pot synthesis of novel 5,11-dioxo-6-methyl-5,9,10,11-tetrahydro-8*H*-naph[2,3:1,2]pyrrolizine and its 9-acetoxy analogue.
Indian J. Chem., **1999**, 38B, 1123.
41. Gadaginamath GS, **Patil SA**.
Synthesis and antimicrobial activity of 2-aminomethyl-5-(4-phenyl-5-mercapto-1,2,4-triazol-3-yl)methoxyindole derivatives.
Indian J. Chem. **1999**, 38B, 1070.
42. Gadaginamath GS, **Patil SA**.
Synthesis and antimicrobial activity of 6-bromo-1-butyl-2-(4-chlorophenoxy) methyl-3-ethoxycarbonyl-5-(4-phenyl-5-mercapto-1,2,4-triazol-3-yl)methoxyindole.
Indian J. Heterocyclic Chem. **1999**, 9, 39.
43. Gadaginamath GS, **Patil SA**.
Synthesis and antimicrobial activity of novel 1-butyl-2-phenoxy/2-phenylthio/2-aminomethyl-5-methoxyindole derivatives.
Polish J. Chem. **1997**, 71, 923.
44. Gadaginamath GS, **Patil SA**, Shyadligeri AS.
Synthesis and Antimicrobial activity of 1,3,4-oxadiazolyl/2,5- dimethylpyrrolyl/1,2,4-triazolylmethoxybisbenzyl)piperzine-2,5-diones.
Indian J. Chem. **1996**, 35B, 681.

ARTICLES PUBLISHED IN CHEMINFORM (articles with novel mechanisms and review articles related to chemistry published in this journal):

45. **Patil SA***, Patil R, Miller DD.
Synthetic applications of the Nenitzescu reaction to biologically active 5-hydroxyindoles.
ChemInform 40(5), **2009**.
46. **Patil SA***, Patil R, Miller DD.
Solid-phase synthesis of biologically important indoles.
ChemInform 40(48), **2009**.
47. **Patil SA***, Patil R, Miller DD.
Synthesis and functionalization of indoles through rhodium-catalyzed reactions.
ChemInform 38(45), **2007**.
48. **Patil S**, Buolamwini JK.
Recent uses of palladium chemistry in indole synthesis.
ChemInform 38(7), **2007**.
49. Dinsmore A, Billing DG, Mandy K, Michael JP, Mogano D, **Patil S**.
Magnesiation employing Grignard reagents and catalytic amine. Application to the

functionalization of *N*-phenylsulfonylpyrrole.
ChemInform 35(24), **2004**.

PAPERS PRESENTED IN CONFERENCES:

1. Kulshrestha A, Beaman K, **Patil S**. Identification of chromene based anticancer agents for ovarian cancer. American Chemical Society National Meeting, Spring **2016**, San Diego, MEDI 290.
2. Patil V, Patil SA, **Patil SA**. Design, synthesis and characterization of novel 5, 6-dimethoxy indanone molecules. American Chemical Society National Meeting, Spring **2016**, San Diego, ORGN 451.
3. Kulshrestha A, Ibrahim SA, Katara GK, Patil R, **Patil S**, Beaman KD. Novel chromene analogs as small-molecule microtubule destabilizers for the treatment of chemo-resistant Ovarian Cancer. American Association of Cancer Research **2016**, New Orleans.
4. Banerjee S, Wang J, Pfeffer S, Ma D, Pfeffer LM, Patil SA, Li W, Miller DD. Design, synthesis and biological evaluation of novel 5H-Chromenopyridines as potential anticancer agents.
41st Annual MALTO Medicinal Chemistry-Pharmacognosy Meeting, **2015**, May 17-19, University of Mississippi, Oxford MS 38677.
5. Tigyi GJ, Patil R, Szabó E, Fells JI, Balogh A, Lim KG, Fujiwara Y, Norman DB, Lee S-C, Balazs L, Thomas F, **Patil S**, Emmons-Thompson K, Boler A, Strobos J, McCool SW, Yates CR, Stabenow J, Byrne GI, Miller DD. Mitigation of the gastrointestinal and hematopoietic acute radiation syndromes by a novel LPA2 receptor-specific non-lipid agonist.
ICRR international conference, Kyoto, Japan, May 25-29, **2015**.
6. **Patil SA**, Pfeffer S, Siebel WL, Pfeffer L, Miller DD. Identification of potent imidazoquinoline derivatives as antiglioma agents from screening.
248th ACS National Meeting, San Francisco, CA, August 10-14, **2014**, MEDI-191.
7. Patil R, Szabó E, Fells JI, Norman DB, Balogh A, Lee S, Balazs L, **Patil S**, Emmons-Thompson K, Yates CR, Tigyi GJ, Miller DD. Design and synthesis of novel sulfamoyl benzoic acid (SBA) analogs as specific non-lipid LPA2 receptor agonists with picomolar affinities.
248th ACS National Meeting, San Francisco, CA, August 10-14, **2014**, MEDI-477.
8. Banerjee S, Wang J, Pfeffer S, Pfeffer L, Li W, Miller DD, **Patil SA**. Design, synthesis, and biological evaluation of novel 4H-chromenopyridines as potential anti-cancer agents.
41st Annual MALTO Medicinal Chemistry-Pharmacognosy Meeting, **2014**, May 18-20, University of Tennessee, Memphis, Tennessee, USA.
9. **Patil SA**, Hosni-Ahmed A, Jones TS, Patil R, Miller DD. Design and synthesis of chromene based novel antiglioma agents.
246th ACS National Meeting & Exposition, Indianapolis, IN, United States, September 8-12, **2013**, MEDI-131.
10. Patil R, **Patil SA**, Hosni-Ahmed A, Jones TS, Miller DD. Synthesis and *in vitro* evaluation of novel 1,2,3,4-tetrahydroisoquinoline derivatives as potent

- anti-glioma agents.
246th ACS National Meeting & Exposition, Indianapolis, IN, United States, September 8-12, **2013**, MEDI-132.
11. Bukiya AN, **Patil SA**, Li W, Miller DD, Dopico AM.
Structural requirements in the steroid lateral chain for the activation of β 1 subunit-containing BK channels by 5 β -cholanic acid-3 α -Ol analogues.
Biophysical Society 57th Annual Meeting, Philadelphia, PA, United States, February 2-6, **2013**, Abstract Number: 2414-Pos.
 12. **Patil SA**, Jones TS, Hosni-Ahmed A, Wang J, Patil R, Li W, Miller DD.
New substituted 4*H*-chromenes as antiglioma agents.
244th ACS National Meeting & Exposition, Philadelphia, PA, United States, August 19-23, **2012**, MEDI-53.
 13. **Patil SA**, Li XS, Siebel WL, Li W, Miller DD.
Design and synthesis of chromenes as novel anti-melanoma agents.
242nd ACS National Meeting & Exposition, Denver, CO, United States, **2011**, Aug. 28th-Sep. 1st, MEDI-016.
 14. Sharma H, **Patil SA**, Neamati N, Schinazi RF, Buolamwini JK.
Synthesis, biological evaluation, molecular modeling and 3D-QSAR studies of 3-keto salicylic acid chalcones as novel HIV-1 integrase inhibitors.
241st ACS National Meeting & Exposition, Anaheim, CA, United States, **2011**, March 27-31, MEDI-327.
 15. Sharma H, Cheng X, **Patil SA**, Buolamwini JK.
Docking and 3D-QSAR studies of HIV-1 integrase inhibitors.
241st ACS National Meeting & Exposition, Anaheim, CA, United States, **2011**, March 27-31, MEDI-78.
 16. **Patil SA**, Bukiya AN, Li W, Dopico AM, Miller DD.
Lithocholic acid-nitriles and tetrazoles as activators of large-conductance, Ca²⁺-activated K⁺ (BK) channels.
239th ACS National Meeting, San Francisco, CA, United States, **2010**, March 21-25, MEDI-214.
 17. Sharma H, **Patil S**, Buolamwini JK.
Docking and 3D-QSAR studies of novel acrylates as GST-p inhibitors. Southeast Medicinal Chemistry, MALTO Meeting; May 23-25, 2010, Oxford, MS. (Podium).
 18. Luo W, Liu J, Li J, Zhang D, Liu M, Addo JA, **Patil S**, Zhang L, Yu J, Buolamwini JK, Chen J, Huang C. Anti-cancer effects of JKA97 are associated with its induction of cell apoptosis via a Bax-dependent and p53-independent pathway. Proc Am Assoc Cancer Res; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr 5490.
 19. Sharma H, **Patil SA**, Buolamwini JK.
CoMFA and CoMSIA 3D-QSAR studies of novel GST-pi inhibitors.
Annual MALTO Medicinal Chemistry-Pharmacognosy Meeting, **2009**, May 17-19, University of Tennessee, Memphis, Tennessee, USA.
 20. **Patil SA**, Bukiya AN, Li W, Dopico AM, Miller DD.
Design and synthesis of hydroxyl-alkynoic acid methyl esters as novel activators of BK channels.
235th ACS National Meeting, New Orleans, USA, **2008**, April 6-10, MEDI 317.
 21. **Patil S**, Lakshman MK.
Synthesis of the sterically hindered 2'-deoxyadenosine adducts of benzo[*c*]phenanthrene diol

epoxides via Pd catalysis.

226th ACS National Meeting, New York, NY, United States, **2003**, September 7-11, ORGN-467.

22. Gadaginamth GS, **Patil SA**.

Triheterocycles : Synthesis and antimicrobial activity of 1,3,4-oxadiazolyl/2,5dimethylpyrrolyl/1,2,4triazolylmethoxybisbenzyl)piperzine-2,5-diones.

32nd Annual Convention of Chemists, Jaipur, India, **1995**, OS-40.

23. **Patil SA**, Gadaginamth GS.

Synthesis and antimicrobial activity of novel 2-phenoxy/2-phenylthio/2-aminomethy-5-(4-phenyl-5-mercapto-1,2,4-triazol-3-yl)methoxyindole derivatives.

34th Annual Convention of Chemists, New Delhi, India, **1997**, ORG(O)-13.

24. Gadaginamth GS, Kavali RR, **Patil SA**.

One pot synthesis of novel 5,11-dioxo-6-methyl-5,9,10,11-tetrahydro-8H-naph[2,3:1,2]pyrrolizine.

Indian Council of Chemists, 16th Conference, Mangalore, India, **1997**, OP-41.

INVITED TALKS:

1. Haim G. And Jane Graumann Nagirner Weinstein Symposium Series talk, Rosalind Franklin University: Identification of Initial Hits as Anticancer Agetns: A Medicinal Chemistry Approach. Monday, September 14th, 2015. Presented by the College of Pharmacy.
2. Pharmacy College, UNTHSC, 3500 Camp Bowie Blvd. Fort Worth, Texas. Design and discovery of antiglioma agents and selective androgen receptor modulators. May, 2014.
3. Pharmacy College, University of Texas at Tyler, Texas. Medicinal chemistry approach to design and discovery of antiglioma agents and androgen receptor modulators. January, 2014.
4. NALCO Naperville, IL. I. Large conductance calcium activated potassium (BK) channel openers; II. HIV 1 intregase inhibitors and their biological evaluation. November, 2008.
5. Southern Research Institute- Birmingham, Alabama. I. Large conductance calcium activated potassium (BK) channel activators; II. Identification of small molecules as HIV 1 intregase inhibitors. April, 2008.
6. Indian Institute of Science, Bangalore, India. I. Design and synthesis of large conductance calcium activated potassium (BK) channel activators; II. Synthesis and biological evaluation of small molecules as HIV 1 intregase inhibitors. August, 2008.

BOOKS/BOOK CHAPTERS:

S. A. Patil*, L. M. Pfeffer , D.D. Miller.

"Gliomas: Classification, symptoms, treatment and prognosis" Edited by David Adamson, contributed chapter titled *Identification of a potent antiglioma agent from pre-clinical screening* (pp. 211-220), **Nova Publishers, 2014**.